Testosterone Replacement Therapy: What the Evidence Actually Shows

Testosterone replacement therapy (TRT) is a prescription medical treatment for diagnosed hypogonadism, not a general-purpose upgrade for energy, ageing or motivation. In men who genuinely have low testosterone, the evidence supports real benefits for sexual function, bone density and lean mass, but little to none for vitality or fatigue. The largest cardiovascular safety trial to date found no increase in major adverse cardiac events, while flagging other risks. TRT also carries trade-offs marketing rarely mentions, including suppression of your own production and effects on fertility, and is usually lifelong once begun.

Important: this article is educational information only. It is not medical advice, and it is not a diagnosis. Testosterone deficiency can only be identified by a qualified physician or endocrinologist using proper blood work and a full clinical assessment. Nobody should start, stop or source testosterone on the basis of an article. If this feels relevant to you, the next step is a conversation with a doctor, not a purchase.

What Testosterone Replacement Therapy Actually Is

TRT supplies testosterone from outside the body to return blood levels to a normal range when the body is not producing enough itself. It treats a diagnosed condition called hypogonadism, in which the testes, or the brain signalling that controls them, are not working properly.

That framing defines who the treatment is for. TRT is replacement, not enhancement: it corrects a documented deficiency rather than pushing a normal man higher. Once the conversation shifts from correcting a deficiency to optimising a healthy man, it has left the evidence base the treatment was built on.

Diagnosed Hypogonadism Versus Marketed Low T

The biggest source of confusion is that two very different things share a name. One is a clinical diagnosis with defined criteria. The other is a marketing category built around symptoms that are common in middle age and have many possible causes.

What an Actual Diagnosis Involves

The Endocrine Society clinical practice guideline on testosterone therapy in men with hypogonadism (Bhasin and colleagues, Journal of Clinical Endocrinology and Metabolism, 2018) sets out a deliberately conservative process:

1. Diagnose only in men with both symptoms and signs of deficiency and unequivocally and consistently low serum testosterone.
2. Use a fasting morning total testosterone measurement, on a reliable assay, as the initial test.
3. Confirm it by repeating that fasting morning measurement, since levels vary day to day and are suppressed by eating.
4. If the result sits near the lower limit of normal, or sex hormone-binding globulin is altered, assess free testosterone properly.
5. Where deficiency is confirmed, investigate why, since the cause can matter more than the number.

Notice how much of that is confirming and ruling out rather than treating. The guideline also lists conditions in which it recommends against starting at all, among them men planning fertility in the near term, breast or prostate cancer, elevated hematocrit, untreated severe sleep apnoea, uncontrolled heart failure, and a recent heart attack or stroke. Structured first-year monitoring is expected too.

How Direct-to-Consumer Low T Marketing Differs

Direct-to-consumer clinics often work from a looser standard. The funnel typically starts with a symptom quiz built around complaints close to universal after 40: tiredness, lower libido, weight gain, poor sleep, low mood. Each has a long list of possible causes, most far more common than hypogonadism.

The differences are structural. A single blood draw at a convenient hour is not two confirmed fasting morning measurements. A symptom score is not a diagnosis. And a business earning revenue only when it prescribes carries an incentive a diagnostic process is meant to exclude. The burden of proof belongs with a physician willing to conclude you do not need treatment.

What the Evidence Shows on Outcomes

Some of the strongest data comes from the Testosterone Trials, coordinated placebo-controlled trials in 790 men aged 65 and over with low testosterone plus symptoms. The results are useful because they are mixed.

Where the Evidence Is Reasonably Strong

Sexual function. In the main Testosterone Trials paper (Snyder and colleagues, New England Journal of Medicine, 2016), a year of treatment significantly increased sexual activity, desire and erectile function versus placebo. The authors called this a moderate benefit, which is a fair description rather than a dramatic one.

Bone density. A companion trial in JAMA Internal Medicine (2017) found one year of treatment in 211 men significantly increased volumetric bone mineral density and estimated bone strength, most in the spine. The caveat is the authors’ own: a larger, longer trial would be needed to show whether that means fewer fractures. Denser bone on a scan is a promising surrogate, not a proven outcome.

Lean mass. A meta-analysis of 16 placebo-controlled trials in men with hypogonadism (Experimental and Therapeutic Medicine, 2016) found increased lean body mass, a pooled mean difference of about 1.2 kg. Fat mass reduction was not statistically significant, and body weight and BMI did not change. A genuine effect, but modest, and nothing like the transformations used in advertising.

Where the Evidence Is Weaker

Energy and vitality. The claim most used to sell TRT is the one the evidence supports least. In the Testosterone Trials, treatment produced no significant benefit for vitality on a validated fatigue scale. Men on testosterone did report slightly better mood and less severe depressive symptoms: real, but limited, and well short of a cure for feeling flat.

Physical function. Similarly modest. Six-minute walking distance did not improve significantly within the dedicated trial. The authors’ overall verdict: moderate benefit for sexual function, some for mood, none for vitality or walking.

The Cardiovascular Safety Question and the TRAVERSE Trial

For roughly a decade, the most serious open question about TRT was whether it raised cardiovascular risk. Conflicting earlier findings led regulators to require a properly powered safety trial. That trial was TRAVERSE.

Published in the New England Journal of Medicine in 2023 (Lincoff and colleagues), TRAVERSE was a randomised, double-blind, placebo-controlled noninferiority trial in 5,246 men aged 45 to 80. All had symptoms of hypogonadism, two fasting testosterone readings below 300 ng/dL, and existing or high-risk cardiovascular disease. Over a mean follow-up of about 33 months, the primary endpoint of cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 7.0 percent on testosterone versus 7.3 percent on placebo (hazard ratio 0.96, 95% confidence interval 0.78 to 1.17), meeting the threshold for noninferiority.

That is genuinely reassuring on the question it was designed to answer, but it needs reading precisely. Noninferior means not worse than placebo on that endpoint; it does not mean beneficial, and it does not mean risk-free. The same trial reported a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism in the testosterone group. It applies to the population enrolled, men with a confirmed diagnosis under medical supervision, and says nothing about men taking testosterone without one. Funding came from AbbVie and others, standard for a regulator-mandated safety study but worth knowing.

The Trade-Offs People Are Often Not Told About

Even where TRT is clearly indicated, it involves commitments best understood before starting rather than discovered afterwards:

• Your own production shuts down. Outside testosterone suppresses the hypothalamic-pituitary-gonadal axis, the feedback loop that tells your body to make its own.
• Fertility is affected. A 2025 review in Asian Journal of Andrology describes azoospermia, the absence of sperm in the ejaculate, as a well-documented consequence of testosterone from an outside source, driven by lower testosterone inside the testes, and it can be temporary or permanent.
• Testicular atrophy is common. With that signal switched off, the testes typically shrink.
• Hematocrit can rise. Testosterone stimulates red blood cell production, which is why the guideline treats elevated hematocrit as a reason not to start and monitors it throughout.
• It is typically lifelong. Because natural production is suppressed, stopping usually means a stretch of symptoms worse than baseline while the axis recovers, if it fully recovers.

None of this argues against TRT for a man who actually needs it. It argues for making the decision carefully, with a specialist, understanding what is being traded.

Who This Decision Belongs To

The honest summary: TRT is an effective treatment for a specific, properly diagnosed condition, and a poor answer to the general experience of getting older. Where hypogonadism is confirmed, it can meaningfully improve sexual function and bone density under supervision. Where testosterone is normal, the evidence does not support it.

Fatigue, low mood, poor sleep and declining strength deserve to be taken seriously precisely because they have so many possible explanations, from thyroid and sleep disorders to depression, medication effects or undertraining. Working out which applies is a job for proper testing, not a quiz.

To repeat the point this article opened with: none of the above is medical advice, and nothing here should be used to self-diagnose or to justify starting, stopping or obtaining testosterone. Those decisions belong to a qualified physician or endocrinologist who can order the right blood work, interpret it against your full history, and monitor you over time. If you think this applies to you, book that appointment.

---

Want more science-backed breakdowns like this one? Subscribe to The Wonder Drop on YouTube for new videos every week.